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In Brief
Luck and Tsai et al. report that altered gut
immunity during obesity contributes to
systemic insulin resistance through
changes in intestinal barrier function,
endotoxemia, fat inflammation, and oral
tolerance to gut luminal antigen.
Targeting gut inflammation with 5-ASA
improves these parameters and
represents a novel treatment approach
for metabolic disease.
Cell Metabolism
ArticleRegulation of Obesity-Related
Insulin Resistance with Gut
Anti-inflammatory Agents
Helen Luck,1,2,9,11 Sue Tsai,1,9,11 Jason Chung,1,11 Xavier Clemente-Casares,1,11 Magar Ghazarian,1,2,11
Xavier S. Revelo,1,11 Helena Lei,1,11 Cynthia T. Luk,1 Sally Yu Shi,1 Anuradha Surendra,3 Julia K. Copeland,3 Jennifer Ahn,2
David Prescott,2 Brittany A. Rasmussen,1 Melissa Hui Yen Chng,4 Edgar G. Engleman,4 Stephen E. Girardin,5
Tony K.T. Lam,1 Kenneth Croitoru,6 Shannon Dunn,2 Dana J. Philpott,2 David S. Guttman,3 Minna Woo,1,6,7
Shawn Winer,1,5,10,11,* and Daniel A. Winer1,2,5,8,10,11,*
1Division of Cellular & Molecular Biology, Diabetes Research Group, Toronto General Research Institute (TGRI), University Health Network,
101 College Street, Toronto, ON M5G 1L7, Canada
2Department of Immunology, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
3Centre for the Analysis of Genome Evolution & Function, University of Toronto, 33 Wilcocks Street, Toronto, ON M5S 3B3, Canada
4Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Palo Alto, CA 94305-5324, USA
5Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
6Institute of Medical Science, Department of Medicine, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
7Division of Endocrinology, Department of Medicine, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto,
ON M5G 2C4, Canada
8Department of Pathology, University Health Network, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
9Co-first author
10Co-senior author
11Present address: 10-352 Toronto Medical Discovery Tower, 101 College Street, Toronto, ON M5G 1L7, Canada
*Correspondence: shawn.winer@utoronto.ca (S.W.), dan.winer@uhn.ca (D.A.W.)
http://dx.doi.org/10.1016/j.cmet.2015.03.001SUMMARY
Obesity has reached epidemic proportions, but little
is known about its influence on the intestinal immune
system. Here we show that the gut immune system
is altered during high-fat diet (HFD) feeding and
is a functional regulator of obesity-related insulin
resistance (IR) that can be exploited therapeutically.
Obesity induces a chronic phenotypic pro-inflam-
matory shift in bowel lamina propria immune cell
populations. Reduction of the gut immune system,
using beta7 integrin-deficient mice (Beta7null), de-
creases HFD-induced IR. Treatment of wild-type
HFD C57BL/6 mice with the local gut anti-inflamma-
tory, 5-aminosalicylic acid (5-ASA), reverses bowel
inflammation and improves metabolic parameters.
These beneficial effects are dependent on adaptive
and gut immunity and are associated with reduced
gut permeability and endotoxemia, decreased
visceral adipose tissue inflammation, and improved
antigen-specific tolerance to luminal antigens. Thus,
the mucosal immune system affects multiple path-
ways associated with systemic IR and represents
a novel therapeutic target in this disease.
INTRODUCTION
Obesity and its associated metabolic abnormalities, including
type 2 diabetes (T2D) and its precursor, insulin resistance (IR),Chave become global diseases that carry considerable morbidity
and mortality (Johnson and Olefsky, 2013). Obesity-related IR
can arise through multiple pathways, but chronic inflammation
in visceral adipose tissue (VAT) has become a prominent patho-
logical mechanism (Gregor and Hotamisligil, 2011; Odegaard
andChawla, 2013). Cells of both the innate and adaptive immune
system residing in VAT have been shown to play a key role in IR.
More specifically, M1 macrophages, interferon (IFN) g-secreting
Th1 T cells, CD8+ T cells, and B cells promote IR, in part, through
secretion of pro-inflammatory cytokines (Lumeng et al., 2007;
Nishimura et al., 2009; Winer et al., 2009a, 2011). In contrast,
Foxp3+ regulatory T cells (Tregs), eosinophils, Th2 T cells, and
type 2 innate lymphoid cells (ILC2) are associated with pro-
tection from IR through local control of VAT inflammation
(Feuerer et al., 2009; Molofsky et al., 2013; Winer et al., 2009a;
Wu et al., 2011).
In addition to VAT, recent evidence has pointed to the bowel
as a key site that becomes altered in obesity-related IR (Johnson
and Olefsky, 2013). These alterations include changes in the
gastrointestinal flora, known as dysbiosis, which can impact
body fat, systemic inflammation, and IR (Ba¨ckhed et al., 2004,
2007; Membrez et al., 2008; Turnbaugh et al., 2006). Under
normal physiological conditions, dysbiosis is kept in check
throughmaintenance of an intact intestinal barrier, characterized
by increased mucus, transforming growth factor (TGF)-b,
interleukin (IL)-10, IL-22, and luminal secretion of IgA (Brown
et al., 2013).
Dysbiosis is believed to cause low-grade inflammation both
systemically, through enhanced leakage of bacterial products
such as lipopolysaccharides (LPS), and locally in the small bowel
and colon (Cani et al., 2007; de La Serre et al., 2010). Systemi-
cally, some of these bacterial products, including gut-derivedell Metabolism 21, 527–542, April 7, 2015 ª2015 Elsevier Inc. 527
antigens, are thought to accumulate and potentiate inflammation
in the VAT (Caesar et al., 2012; Wang et al., 2010). Thus, manip-
ulation of the gut barrier to reduce LPS leakage (e.g., with IL-22)
improves insulin sensitivity (Wang et al., 2014). In the bowel,
increased tumor necrosis factor alpha (TNF-a) and NF-kB acti-
vation occurs in the ileum, while IL-1b and IL-12p40 levels are
elevated in colons of HFD-fed mice (Ding et al., 2010; Li et al.,
2008). However, the local effects of HFD on most immune cell
populations in the gut and their function in IR remain unclear.
In IR and T2D, treatment with systemic anti-inflammatory ther-
apies such as salicylates and IL-1b antagonists has shown some
efficacy in clinical trials (Goldfine et al., 2010; Larsen et al., 2007),
and systemic targeting of T and B cells has shown effects in
rodent models (Winer et al., 2009a, 2011). However, many sys-
temic immune modulators carry potential serious side effects;
thus, the development of locally active, well-tolerated, and effi-
cient therapies is a principal goal of IR therapy research. One
locally active, gut-specific anti-inflammatory agent is mesal-
amine (5-ASA), a first-line maintenance therapy for inflammatory
bowel disease (IBD) (Rousseaux et al., 2005). 5-ASA is a salicylic
acid derivative with anti-inflammatory properties that acts locally
in the gut with minimal systemic absorption and side effects.
As IBD is characterized by increased intestinal inflammation
and altered permeability (Brown et al., 2013), we hypothesized
that 5-ASA might have beneficial effects in obesity-related IR
and may help elucidate roles of gut immune cells in this disease.
Here, we show that the gut immune system is an important
modulator of IR. Diet-induced obesity (DIO) is accompanied
by a low-grade pro-inflammatory shift in lamina propria (LP) im-
mune cell polarity, consistent with changes previously described
in response to an intestinal barrier defect (Brown et al., 2013).
Targeting these changes may lead to new classes of potentially
effective, minimal-side-effect therapies for IR.
RESULTS
HFD Induces a Pro-Inflammatory Shift in Intestinal
Immune Cell Populations
To examine the effects of DIO on gut immunity, we first investi-
gated if adaptive immune cell populations in the colon and
small bowel LP are altered by HFD feeding in C57BL/6 mice at
3 or 12–16 weeks of HFD. After 3 weeks of HFD, changes in
the proportions of bowel immune populations began in the
colon, including a reduced percentage of Tregs and an increase
in IL-17-producing gd T cells (Figures S1A and S1B). However,
after 12–16 weeks of diet, HFD induced a pro-inflammatory shift
in immune cells in both the colon and small bowel. In colonic
immune cells, there was an increase in the proportion and/or
absolute number of IFNg-producing Th1 T cells and CD8+
T cells and reduction in the proportion of CD4+ Foxp3+ Tregs
(Figure 1A; Figure S1C). In the small bowel of HFD mice, there
was an increase in the frequencies and/or numbers of Th1
CD4+ T cells and IFNg-producing CD8+ T cells and a decrease
in the proportion and absolute number of CD4+ Foxp3+ Tregs
(Figure 1B; Figure S1D). We next assessed the effects of
12–16 weeks of HFD feeding on gd T cells and innate lymphoid
cell populations in the bowel. HFD increased the frequency
and/or number of IL-17-producing but not IFNg-producing gd
T cells in the colon and small bowel (Figures 1C and 1D; Figures528 Cell Metabolism 21, 527–542, April 7, 2015 ª2015 Elsevier Inc.S1C and S1D). Furthermore, there was an increase in total cell
numbers of innate lymphoid cells in the colon, though the relative
proportion of NKp46+ CD4 cells was reduced in HFD-fed mice
(Figure S1E).
To determine if humans showed similar changes in gut
immune populations during obesity, we correlated patient BMI
with relative numbers of pro-inflammatory T-bet+ (Th1, ILC1
[Bernink et al., 2013]) T cells, anti-inflammatory Foxp3+ (Treg)
T cells, and CD8+ T cells in the LP of colon and ileum resection
specimens. Table S1 summarizes relevant clinical parameters of
patients included in the study. Obese patients showed increases
in colon and small bowel T-bet+ cells and CD8+ cells and a
reduction in Tregs (Figures 1E and 1F).
Collectively, these results demonstrate a reduction in gut
Tregs and a pro-inflammatory shift in some adaptive and innate
T cell populations in the gut of HFD-fed mice, with a similar
observation in our specific cohort of obese humans. Interest-
ingly, this inflammatory shift was not associated with any
apparent histological changes of chronic or active inflammation
on H&E-stained sections of obese human (Figure S1F, top) or
HFD-fed mouse colons (Figure S1F, bottom).
Beta7 Integrin-Deficient Mice Are Protected
from HFD-Induced IR
We next determined if the gut immune system as a whole could
contribute to the development of obesity-associated IR. We
placed beta7 integrin-deficient C57BL/6 mice (Beta7null mice)
on either normal chow diet (NCD) or HFD for 12 weeks and
then assessed metabolic parameters. Beta7 pairs with alpha4
integrin on leukocytes to form the mucosal addressin molecule
LPAM-1, and mice deficient in beta7 show hypoplasia of gut
lymphoid tissue due to reduced homing of leukocytes to colon
and small bowel (Wagner et al., 1996). Consistently, we
observed a reduction mainly in the absolute numbers but not
proportions of most immune cells, especially in IFNg-producing
T cell subsets in the LP of colons and small bowels of Beta7null
mice after 12 weeks of HFD (Figure 2A; Figure S2A). There
were no differences in the relative proportions of these subsets
in the spleen (Figure S2B), suggesting that the lack of beta7 in-
tegrin does not attenuate systemic immunity.
In terms of metabolic parameters, there were no differences in
weight gain during 12 weeks of HFD feeding between wild-type
(WT) and Beta7null mice (Figure 2B). Interestingly, Beta7null mice
demonstrated improved fasting glucose, glucose tolerance
(using glucose tolerance test, GTT), and insulin sensitivity (using
insulin tolerance test, ITT) compared to WT mice after 12 weeks
of HFD (Figure 2C). These mice also showed similar food intake,
oxygenconsumption, andcarbondioxideproduction (Figure 2D).
Histological analysis of bowels in HFD-fed Beta7null mice did not
show signs of active colitis (Figure S2C). Interestingly, HFD-fed
Beta7null mice presented no difference in adipocyte size, but
showed a marked reduction in crown-like structures (CLS)
in the VAT, along with reduced liver steatosis (Figure 2E;
Figure S2D). Consistent with the reduced CLS, HFD Beta7null
mice had overall less VAT immune cell infiltrates (Figures S2E–
S2J). This change was likely not due to the beta7 integrin
deficiency imparting an intrinsic defect on T cells to home to
VAT, as Beta7null T cells were equally capable at trafficking
and engrafting to VAT upon transfer as their WT counterparts
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Figure 1. HFD Is Associated with a Pro-inflammatory Shift in Intestinal Immune Cells
(A and B) Intracellular cytokine staining in T cells from colon (A) or small bowel (B) LP after 12–16 weeks of HFD (*p = 0.005 for Th1, *p = 0.02 for CD8, *p = 0.02 for
Tregs, n = 3–4 experiments, 8–10 mice for colon; *p = 0.03 for Th1, *p = 0.046 for CD8, *p = 0.002 for Tregs, n = 5–6 experiments, 10–12 mice for small bowel).
(C and D) Intracellular cytokine staining in gd T cells from colon (C) or small bowel (D) LP after 12–16 weeks of HFD (*p = 0.02 for colon, *p = 0.001 for small bowel;
n = 4 experiments, 10 mice for colon and n = 4–5 experiments, 10 mice for small bowel).
(E) T-bet (far left), Foxp3 (middle), and CD8+ (far right) staining in colon and ileum of human subjects with lean or obese BMI (*p = 0.04, n = 7 for colon, *p = 0.02,
n = 3–4 for ileum for T-bet; *p = 0.005, n = 7 for colon, *p = 0.047, n = 3–4 for ileum for Foxp3; *p = 0.03, n = 7 for colon, *p = 0.006, n = 3–4 for ileum for CD8+).
(F) Representative images of double staining for T-bet (red, examples indicated by blue arrows) and Foxp3 (brown, examples indicated by black arrows) (top and
third row) and CD8+ stain (brown) (second and last row) in lean (left) versus obese (right) colons (top four quadrants) and ileums (bottom four quadrants).
Scale bar: 100 mm. HPF: high-power field. 403 objective. HPF = 0.237 mm2. Data in bar graphs represent mean ± SEM.
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Figure 2. Intestinal Immune Cells Influence Glucose Homeostasis
(A) Absolute cell counts, including CD45+ (top far left), CD3+ (top middle left), CD3+ CD4+ or CD3+ CD8+ (top far right), CD4+ subsets (bottom far left), IFNg+
CD8+ (bottom middle), and gd+ T cell subsets (bottom far right) from colon and small bowel (SB) LP after 12 weeks of HFD in WT and Beta7null (Beta7null) mice.
Entire colons were processed, or the distal 10 cm of SB (jejunum + ileum). *p = 0.0008 for CD45 colon, *p < 0.0001 for CD45 SB; *p = 0.045 for CD3 colon,
*p = 0.0004 for CD3 SB; *p = 0.009 for CD4 colon, *p = 0.0006 for CD4 SB, *p < 0.0001 for CD8 SB; *p = 0.02 for gd SB; *p = 0.0008 for CD4 IFNg colon; *p = 0.008
for CD4 IFNg SB; *p = 0.03 CD8 IFNg SB; *p = 0.001 for gd IL-17 colon, n = 4 experiments, 8–11 mice.
(B) Body weights of WT and Beta7null mice fed HFD over time, starting at 6 weeks of age (n = 13 WT, n = 11 Beta7null mice).
(C) Fasting glucose (left), GTT (middle), and ITT (right) of 12-week HFD-fed WT and Beta7null mice (*p < 0.05, n = 13–15 WT, n = 7–9 Beta7null mice).
(D) Food intake (left), metabolic cage analysis including oxygen consumption (left middle), carbon dioxide production (right, middle), and respiratory exchange
ratio (RER) (right) of HFD WT and Beta7null mice (n = 7 for food intake, n = 7 WT and n = 6 Beta7null mice for metabolic cage analysis).
(legend continued on next page)
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(Figure S2K). When Beta7null mice were fed a NCD, we saw little
differences in body weight (Figure S2L), fasting glucose, or insu-
lin tolerance, but some mild improvements in glucose tolerance
(Figure S2M), suggesting that functional glucose modulation
by the gut immune system is more pronounced in the setting
of HFD but may also be relevant to a lesser degree under normal
physiological conditions such as a NCD. Collectively, these
results demonstrate that changes to the makeup of the gut
immune system may have ramifications in the development of
obesity-associated IR.
The Gut Anti-inflammatory 5-ASA Alleviates
HFD-Associated Metabolic Disease
Since obesity is associated with a pro-inflammatory shift in gut
immune populations, and the composition of a gut immune sys-
tem is important in the development of disease, we reasoned
that therapies aimed at targeting gut inflammation such as me-
salamine (5-ASA) may have a role in the treatment of metabolic
disease.We first fedmice beginning at 6 weeks of agewith either
HFD or HFD incorporated with 5-ASA (1,500 mg/kg/day). After
12–14 weeks of HFD, there was no significant difference in
bodyweight (Figure 3A, left), VATweight (Figure 3A, right), adipo-
cyte size (Figure 3B, left), number of crown-like structures in VAT
(Figure 3B, right, and Figure S3A top), or organ weights between
groups (Figure S3B). Although we did observe reduced liver
steatosis in the 5-ASA-treated group (Figure S3A, bottom), we
could not detect significant changes in gluconeogenesis enzyme
gene expression, in spite of trends to lower expression with
5-ASA treatment (Figure S3C). There were also no effects of
5-ASA on expression of adipogenesis-related genes in either
VAT or subcutaneous adipose tissue (SAT) (Figure S3D). Further-
more, there was no difference in food intake, oxygen consump-
tion, carbon dioxide output, or respiratory exchange ratio
(RER) (Figures S3E and S3F). However, mice receiving 5-ASA
showed improvements in fasting glucose (Figure 3C, left), fasting
insulin (Figure 3C, right), glucose tolerance (Figure 3D, left),
and insulin tolerance (Figure 3D, right). Consistent with improved
insulin tolerance, 5-ASA-treated mice showed increased phos-
phorylated-Akt/Akt ratio in VAT, liver, and muscle with insulin
challenge (Figure 3E). Similar to the higher dose used, a lower
dose (150 mg/kg/day) of 5-ASA also exerted beneficial effects
on metabolic disease (Figures S3G and S3H).
We next assessed whether 5-ASA could be used to treat
established obesity-associated IR. C57BL/6 mice on HFD for
8 weeks, with established metabolic disease, were switched
onto a HFD with 5-ASA for 8 additional weeks and compared
to mice on only HFD from the beginning. Similar to the preventa-
tive protocol, 5-ASA did not change body weight (Figure 3F), but
did produce significant improvements in glucose tolerance and
insulin tolerance (Figure 3G). To assess whether the beneficial
metabolic effects of 5-ASA require a HFD-induced milieu, we
placed 6-week-old C57BL/6 mice on either NCD or NCD with
5-ASA (1,500 mg/kg/day). After 12 weeks of treatment, there(E) Relative fat cell diameter (left) of mice, or number of VAT ‘‘crown-like structure
fields counted from n = 3 mice). Data in bar graphs represent mean ± SEM.
Cwas little or no difference in body weight, fasting glucose,
glucose tolerance, or IR (Figure S3I). These results suggest
that the use of 5-ASA has specific therapeutic effects on glucose
homeostasis in the setting of DIO.
5-ASA Improves Bowel and VAT Inflammation
in HFD Mice
To begin understanding the mechanisms by which 5-ASA can
exert effects on glucose homeostasis, we examined the effects
of 5-ASA on systemic and local immune function during HFD
feeding. 5-ASA treatment showed no effects on immune cell
populations in the spleen (Figure S4A), on stimulated spleen
immune cell cytokine secretion, or on circulating immune cell
polarity in the blood (Figures S4B and S4C). Similarly, serum
levels of cytokines in mice treated with 5-ASA were mostly un-
changed, though we did identify a significant but small increase
in RANTES and a reduction in TNF-a (Figure S4D). Consistent
with little systemic effects on immune cell function, we could
identify only traces of 5-ASA compound in the serum of mice,
including mice treated with high-dose 5-ASA for 12 weeks, by
use of high-performance liquid chromatography (HPLC) with
an internal 4-ASA standard (Figure S4E, left). Instead, 5-ASA
was concentrated in the colon and small bowel (approximately
203 enriched compared to serum, given the density of tissue),
and importantly, 5-ASA was undetectable in VAT (Figures S4E,
right, and S4F). Consistently, as mentioned previously, 5-ASA
did not alter expression of adipogenesis-related genes in VAT
or SAT (refer back to Figure S3D). The results are in agreement
with previous literature demonstrating poor systemic absorption
of 5-ASA upon oral administration (Rousseaux et al., 2005) and
highlight the relative specificity of our gut anti-inflammatory
therapy.
Consistent with a dominant anti-inflammatory effect in the
gut, 5-ASA treatment showed an overall reversal of the local
pro-inflammatory immune shift in both the colon (Figure 4A)
and small bowel (Figure 4B), characterized by a reduction in
Th1 cells, IFNg-secreting CD8+ T cells, and IL-17-secreting
gd T cells. There was also an increase in Tregs in the
small bowel (Figure 4B). Interestingly, associated with the
anti-inflammatory changes in the bowel, 5-ASA also reversed
local VAT inflammation by reducing percentages of Th1 cells,
IFNg-secreting CD8+ T cells (Figure 4C), and M1 inflammatory
macrophages (Figure 4D) in VAT while increasing Tregs (Fig-
ure 4C, third from left). Significant anti-inflammatory effects
on immune cell populations were not seen in the bowels or
VATs of NCD 5-ASA-treated mice compared to untreated
NCD mice, suggesting that an increased inflammatory environ-
ment was needed to elicit significant differences in immune
cell populations (Figures S5A–S5D). In line with the anti-inflam-
matory changes in gut immune populations seen with HFD
5-ASA-fed mice, HFD 5-ASA treatment was also associated
with shifts in gut bacteria that are typically seen with adminis-
tration of the drug, including increased bacterial diversity,s’’ (CLS) per 1003 low power field (right), after 12 weeks of HFD (*p < 0.0001,
ell Metabolism 21, 527–542, April 7, 2015 ª2015 Elsevier Inc. 531
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Figure 3. 5-ASA Improves Systemic Metabolic Parameters during HFD Feeding
(A) Left: body weights of HFD andHFD 5-ASA (1,500mg/kg/day)-fed C57BL/6mice over time, starting at 6 weeks of age (n = 10). Right: VAT weights of mice, after
14 weeks of HFD or HFD 5-ASA (1,500 mg/kg/day) (n = 10).
(B) Relative fat cell diameter of mice (left) or number of VAT ‘‘crown-like structures’’ (CLS) (right) per 1003 low power field, after 14 weeks of HFD or HFD 5-ASA
(1,500 mg/kg/day) (n = 3).
(C and D) Fasting glucose (C, left), fasting insulin (C, right), glucose tolerance test (GTT, D, left), and insulin tolerance test (ITT, D, right) of mice after 14 weeks of
HFD or HFD 5-ASA (1,500 mg/kg/day) (*p = 0.001 for glucose, n = 10 mice, *p = 0.02 for insulin, n = 8–9 mice, *p < 0.05 for tolerance testing, n = 10 mice for GTT,
n = 13–15 mice for ITT).
(E) Left: insulin signaling in VAT, liver, and muscle of NCD, HFD, and HFD 5-ASA-fed mice injected with (+) or without () insulin and immunoblotted for pAkt and
total Akt proteins (image shown is representative of 1 of 3 experiments with similar results, n = 3–4 mice). Right: fold change of pAkt/Akt protein ratios in mice fed
HFD 5-ASA relative to HFD-fed controls (*p% 0.01, n = 4 mice for VAT, 3–4 mice for liver and muscle).
(F and G) Body weights (F), GTT (G, left), and ITT (G, right) after 8 weeks of HFD or HFD 5-ASA (1,500 mg/kg/day) in mice switched over from 8 weeks of HFD
(*p < 0.05, n = 5 mice, GTT was performed with an i.p. glucose challenge at a dose of 1.0 g/kg). Data in bar graphs represent mean ± SEM.
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Figure 4. 5-ASA Improves Gut and VAT Inflammation in Mice during HFD Feeding
(A and B) Intracellular staining of cytokines and Foxp3 in LP T cell populations in the colon (A) or small bowel (B) of mice after 16 weeks of HFD or HFD 5-ASA
(1,500 mg/kg/day) (*p = 0.001 for Th1, *p = 0.01 for CD8, *p = 0.045 for gd T cell IL-17, n = 2–3 experiments, 9 mice for colon; *p = 0.01 for Th1, *p = 0.02 for CD8
IFNg, *p = 0.005 for Treg, *p = 0.03 for gd T cell IFNg, *p < 0.0001 for gd T cell IL-17, n = 2–4 experiments, 6–8 mice for small bowel).
(C and D) Flow cytometriy analysis of T cell (C) andM1macrophage subset (D) in VAT of mice after 16weeks of HFD or HFD 5-ASA (1,500mg/kg/day) (*p = 0.03 for
Th1, *p = 0.02 for CD8, *p = 0.03 for Treg, *p = 0.01 for macrophages, n = 2 experiments, 8 mice). Data in bar graphs represent mean ± SEM.
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Figure 5. 5-ASA Targets Adaptive Gut Immunity in a PPARg-Dependent Manner during HFD Feeding
(A and B) Body weights (A), GTT (B, left), and ITT (B, right) of Rag1null mice after 8 weeks of HFD or HFD 5-ASA (1,500 mg/kg/day) (n = 4–5 mice).
(C) Body weights of Beta7null mice after 14 weeks of HFD or HFD 5-ASA (n = 15 HFD Beta7null, n = 11 HFD 5-ASA Beta7null).
(D) Fasting glucose (left), GTT (middle), and ITT (right) of Beta7null mice after 12 weeks of HFD or HFD 5-ASA (n = 9 HFD Beta7null, n = 10 HFD 5-ASA
Beta7null).
(E) PPARg mRNA expression of small bowel (SB) T cells compared to splenic T cells isolated from HFD-fed C57BL/6 mice (*p = 0.004, n = 3 mice).
(F) PPARg transcription factor activity of SB T cells from HFD- or HFD 5-ASA-fed mice (*p = 0.04, n = 4 mice, normalized to total nuclear protein).
(G) Levels of secreted IFNg cytokine from small bowel (SB) T cells (left) or splenic (SP) T cells (right) from HFD-fed WT mice compared to HFD-fed Lck-Cre+
PPARgfl/fl mice treated with the indicated doses of 5-ASA in vitro (*p% 0.02 at all doses of 5-ASA for small bowel T cells, n = 3 mice).
(legend continued on next page)
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increased Firmicutes, and increased Clostridiales (Figures S6A–
S6E) (Andrews et al., 2011).
5-ASA Targets Adaptive Gut Immunity and PPARg
To determine if the effects of 5-ASA were mediated through anti-
inflammatory actions that require adaptive immune cells rather
than direct effects on gut epithelium, we treated 6-week-old
Rag1null mice with HFD 5-ASA. Preventative treatment of Rag1-
null mice with HFD 5-ASA had no effect on body weight, glucose
tolerance, or IR (Figures 5A and 5B), suggesting that the benefi-
cial effects of 5-ASA required components of the adaptive im-
mune system. To further pinpoint the location of 5-ASA action
on glucose tolerance, we fed Beta7null mice a HFD with 5-ASA.
Interestingly, similar to the Rag1null mice, treatment with 5-ASA
had no major effects on glucose tolerance and IR (Figures 5C
and 5D). Thus, the beneficial metabolic effects of 5-ASA require
an ‘‘intact’’ gut immune system.
Since knock-out studies linked potential effects of 5-ASA on
glucose metabolism to the gut immune system, and 5-ASA has
been reported to possess PPARg agonist properties (Rousseaux
et al., 2005), we next determined if 5-ASA could be directly influ-
encing intestinal immune cell function in HFD through targeting
PPARg. As the effects of 5-ASA were more robust with small
bowel T cells than colonic T cells, we focused our studies on
small bowel T cells. Indeed, we observed higher PPARg gene
expression in small bowel T cells compared to total splenic
T cells in both HFD and NCD-fed mice (Figure 5E; Figure S5E).
Mice fed HFD 5-ASA showed increased PPARg functional activ-
ity in purified small bowel T cells compared to those fedwith con-
trol HFD (Figure 5F). We next tested if 5-ASA can suppress IFNg
production in vitro. Indeed, similar to another PPARg agonist, ro-
siglitazone, 5-ASA reduced IFNg production by anti-CD3/CD28-
activated small bowel but not splenic T cells (Figure S5F).
Furthermore, loss of PPARg in T cells (Lck-Cre PPARgfl/fl) abro-
gated the suppressive effects of 5-ASA, confirming that 5-ASA
acts in a PPARg-dependent manner (Figure 5G). In addition, 5-
ASA indirectly reduced T cell IFNg expression by modulating in-
testinal dendritic cell function, as shown by reduced IFNg levels
in antigen-specific co-culture systems using OT-II CD4+ T cells
and 5-ASA-pre-treated small bowel but not splenic dendritic
cells (Figure 5H).
5-ASA and Reduced Gut Inflammation Improve
Intestinal Barrier Function during HFD
Since both DIO and intestinal inflammation are associated with
impairment of the gut epithelial barrier, which can trigger sys-
temic endotoxemia and IR (Cani et al., 2007; Wang et al.,
2014), we next investigated the effects of 5-ASA on intestinal
permeability and on serum and VAT endotoxin levels. 5-ASA
treatment induced significant improvements in intestinal epithe-
lial barrier permeability, as measured by fluorescence FD4 assay
(Figure 6A), which is consistent with the reduced gut immune cell(H) Levels of secreted IFNg cytokine fromOT-II T cells stimulated with 5-ASA-treat
presenting the indicated concentrations of OVA323-339 peptide (*p% 0.03, n = 3
Data in bar graphs represent mean ± SEM.
Cinflammatory shift and overall improvement in glucose homeo-
stasis previously observed. Moreover, IgG responses to LPS
were markedly diminished in 5-ASA-treated mice (Figure 6B,
left) accompanied by reduced levels of serum endotoxin (Fig-
ure 6B, middle). VAT endotoxin levels also trended lower in 5-
ASA-treated mice, though this result did not reach significance
(Figure 6B, right). Taken together, these results show effects of
5-ASA on reducing HFD-induced gut leakage to endotoxins.
Because HFD 5-ASA reduces IFNg expression compared to
control HFD and is associated with improvements in intestinal
permeability, we next assessed the role of IFNg in intestinal
permeability during HFD feeding. HFD-fed IFNg-deficient mice
showed improved intestinal barrier function as reflected in
reduced plasma FD4 levels (Figure 6C, left). IFNg was also
able to reduce ZO-1 tight junction gene expression in intestinal
epithelial cells, suggesting one possible mechanism for its ability
to influence gut permeability (Figure 6C, right). Thus, the shifts in
HFD bowel immune cells to IFNg-producing immune cells likely
impact metabolic function at the level of intestinal permeability.
To further corroborate this notion, we assessed bowel perme-
ability in Beta7null mice, which showed reduced numbers of
intestinal immune cells that most prominently affected IFNg-
expressing T cells. Beta7null mice showed improved/reduced
intestinal permeability as measured by FD4 assay and reduced
anti-LPS IgG (Figures 6A and 6B, left).5-ASA Promotes Oral Tolerance
While permeability-related gut-derived endotoxin alone may
contribute to VAT inflammation and potentially IR (Caesar
et al., 2012), it is thought that this trigger works alongside other
gut-associated antigens to activate antigen-specific T cells in
VAT, thereby influencing glucose homeostasis (Wang et al.,
2010). Thus, to further understand how a gut-specific anti-in-
flammatory agent may contribute to reduced inflammation in
VAT, we examined the effects of 5-ASA on oral immune toler-
ance to a gut-derived antigen. NCD-, HFD-, or HFD 5-ASA-fed
C57BL/6 mice were administered oral ovalbumin (OVA) antigen
for 1 week prior to immunization with OVA-CFA. Interestingly,
HFD 5-ASA-fed mice showed a stronger oral tolerance response
to OVA antigen systemically, as reflected by an increased OVA-
specific IgG1/IgG2c ratio (indicative of reduced Th1 inflamma-
tory responses), and a nearly 3-fold increase in OVA-specific
IgA (Figure 6D). Moreover, draining lymph nodes in mice fed
HFD 5-ASA demonstrated a reduction in OVA-specific T cell-
derived IL-2 and IFNg, which is also consistent with the improved
oral tolerance and reduced antigen-specific inflammation to gut
antigen (Figure 6E). Finally, 5-ASA treatment induced a nearly 4-
fold increase in antigen-specific Tregs to OVA in VAT as
measured using OVA/I-Ab tetramers (Figure 6F). Collectively,
the data suggest that reducing low-grade inflammation in the
gut during HFD feeding can impact multiple pathways associ-
ated with IR, including gut barrier function, tolerance toed (0.1 or 1.0 mM) or untreated splenic (left) or small bowel (right) dendritic cells
samples, 3 spleens; n = 2 samples, 4 pooled bowels).
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Figure 6. 5-ASA and Reduced Gut Inflammation Improve Intestinal Barrier Function and Oral Tolerance during HFD Feeding
(A) Plasma FD4 concentration of age-matched NCD WT, HFD WT, HFD 5-ASA WT, and HFD Beta7null mice after 12–16 weeks of diet following oral gavage as a
measure of intestinal permeability (*p = 0.02 for NCD Control versus HFD Control, *p = 0.04 for HFD Control versus HFD 5-ASA, and *p = 0.04 for HFD Control
versus HFD Beta7null; n = 10 for NCD Control, n = 10 for HFD Control, n = 8 for HFD 5-ASA, and n = 6 for HFD Beta7null mice).
(B) Far left: serum anti-LPS IgG levels of age-matchedNCDWT, HFDWT, HFD 5-ASAWT, andHFDBeta7null mice after 14weeks HFD (*p% 0.03, n = 5–8). Middle
and far right: serum endotoxin levels (middle) and VAT endotoxin levels (right) of age-matched NCD WT, HFD WT, and HFD 5-ASA WT after 14 weeks HFD
(*p < 0.05 for serum endotoxin, p = 0.19 for VAT endotoxin; n = 3–4 for serum endotoxin, n = 5 for VAT endotoxin).
(C) Left: plasma FD4 concentrations, following oral gavage, of age-matched IFNgnull mice after 10 weeks of HFD (*p = 0.01, n = 4 mice). Right: ZO-1 mRNA
expression relative to housekeeping gene expression in MODE-K intestinal cells treated with indicated amounts of IFNg in vitro (*p = 0.006, n = 3 in each
treatment).
(D) Ratio of OVA-specific IgG1/IgG2c (left) and OVA-specific IgA (right) in age-matched NCDWT, HFDWT, and HFD 5-ASAWTmice 2 weeks after immunization
with OVA-CFA (*p = 0.03 for IgG1/IgG2c, *p = 0.03 for oral NCD versus oral HFD IgA, *p = 0.02 for oral HFD versus oral HFD 5-ASA IgA; n = 4–6 mice).
(legend continued on next page)
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gut-derived antigen, and antigen-specific immunity to gut-
derived antigen in VAT. Taken together, these results suggest
that anti-inflammatory targeting of gut immune cells is a novel
approach to treat obesity-related IR.
DISCUSSION
We have identified the gut immune system as an active orches-
trator and therapeutic target in obesity-related IR. Previous work
has shown that HFD increases ileal TNF-a mRNA, induces
expression of TLR4 and NF-kB in small bowels (Ding et al.,
2010; Wang et al., 2013), and increases IL-1b, IL-12p40, NF-
kB, and TLR4 in colons of DIO mice (Kim et al., 2012; Li et al.,
2008). Consistently, we show that DIO promotes a pro-inflam-
matory shift in gut immune cell populations, characterized by
reduced LP Foxp3+ Treg cells, increased IFNg-producing Th1
and CD8+ T cells, as well as increased IL-17-producing gd
T cells. Similar to the changes in mice, altered ratios of T-bet+
cells—Foxp3+ Treg cells, as well as changes in CD8+ T cells—
were found in both small and large bowels of obese humans,
though these studies involved the use of negative margin spec-
imens from patients with tumors and thus need more rigorous
follow-up in additional cohorts of patients, including bariatric
patients. A recent report has also demonstrated reduction in
IL-22 in the gut of obese mice post-immune challenge (Wang
et al., 2014). Consistently, we saw reduced percentages of
NKp46+ CD4 ILCs, which are important producers of IL-22.
Moreover, the pro-inflammatory shift in immune cell populations
observed in the gut was not associated with obvious inflamma-
tory histological changes, and so we classify this pro-inflamma-
tory shift as a sub-histological change, or ‘‘low-grade subclinical
inflammation.’’
We next investigated if the gut immune system as a whole
could exert systemic effects on glucose homeostasis. In this
model, we used Beta7null mice, which have marked hypoplasia
of the gut lymphoid system. We noted improved metabolic
parameters in the Beta7null mice despite similar body weights.
These mice showed reduced immune cell infiltrates in the gut
during HFD, including reductions in IFNg-producing CD4+ and
CD8+ T cells, consistent with a potential pathogenic role for
some intestinal immune cells in DIO. However, additional work
is needed to rule out whether other off-target effects of this
molecule, such as potential traffic to other tissues, exist in the
setting of DIO that might also contribute to the phenotype.
Furthermore, Beta7null mice are susceptible to bacterial over-
growth (Wagner et al., 1996), which can cause changes in
the microbiome and contribute to the observed phenotype.
This phenotype may be similar to lymphotoxin-deficient mice
that show hypoplasia of Peyer’s patches and improved glucose
tolerance due to altered gut colonization of segmented filamen-
tous bacteria (SFB) and reduced energy-harvesting bacteria
(Upadhyay et al., 2012). Nonetheless, taking together the
phenotypic data of both models, it appears that active gut(E) OVA-specific recall IL-2 and IFNg responses in age-matched HFD WT and HF
OVA-CFA (*p = 0.01 for IL-2, *p = 0.006 for IFNg; n = 4–5 mice in duplicates).
(F) OVA tetramer-stained Treg cells from VAT of age-matched oral or non-oral c
OVA-CFA (*p = 0.03; n = 2 experiments, 6 pooled mice). Data in bar graphs repr
Cinflammation contributes to downstream pathways, ultimately
leading to obesity or related IR. Potential pathways includemod-
ulation of the gut flora with effects on energy-harvesting bacteria
(Upadhyay et al., 2012), bile acid and short-chain fatty acid
release (Brown et al., 2013), modulation of the gut epithelial
barrier (Pastorelli et al., 2013), control of gut hormone release
such as GLP-1 leading to hyperinsulinemia (Kahles et al.,
2014), and/or a role in dictating inflammatory responses to gut-
derived antigen and endotoxin (Caesar et al., 2012; Wang
et al., 2010).
In HFD Beta7null mice, we observed overall improvements in
gut barrier function, characterized by reduced FD4 and anti-
LPS response. These findings are potentially linked to reduced
infiltrates of IFNg-producing cells in the bowel, as IFNg has
direct pathological effects on disrupting barrier function
(Beaurepaire et al., 2009). Consistently, HFD IFNgnull mice have
improved barrier function compared to HFD WT mice, impli-
cating local intestinal IFNg production as one critical pathogenic
mediator of intestinal permeability in DIO.
The overall HFD-induced phenotype of intestinal immune cells
observed in WT mice is consistent with changes described in
other diseases characterized by breech of intestinal barrier, dys-
biosis, and subsequent anti-bacterial immune response (Brown
et al., 2013; Petnicki-Ocwieja et al., 2009). LP CD4+ Foxp3+
Tregs, in particular, are critical in maintaining a tolerant response
to gut microbiota and are reduced in the presence of intestinal
barrier defects. In healthy hosts, Tregs maintain the intestinal
barrier through promotion of TGF-b-dependent microbiota-
specific IgA responses (Cong et al., 2009). Upon breech of the
barrier, Tregs suppress Th1 responses via IL-10 and TGF-b
(Cong et al., 2009). Our observed HFD-associated reductions
in LP Tregs and increases in pro-inflammatory IFNg-secreting
Th1 and CD8+ cells, as well as IL-17-producing gd T cells, are
thus consistent immunologically with intestinal barrier breech.
Several studies have shown that DIO is associated with a breech
in the intestinal barrier, leading to increases in circulating levels
of gut-derived microbial products, such as LPS (Cani et al.,
2007, 2008). In addition to direct leakage, gut-derived LPS can
be transported along with chylomicrons into circulation (Ghoshal
et al., 2009). While we described one mechanism of immune cell
IFNg-mediated effect on the intestinal barrier during DIO, it is
possible that changes in IL-10, associated with reduced
Tregs, or altered inflammatory status of the intestinal epithelial
cells may also contribute to decreased barrier function. Indeed,
IL-10 has been shown to promote intestinal barrier mucin
production (Hasnain et al., 2013), while a recent study showed
improvements in gut barrier function in HFD mice lacking the
pro-inflammatory molecule, MyD88, only in intestinal epithelial
cells (Everard et al., 2014). In the latter study, knockdown
of intestinal epithelial MyD88 also improved glucose homeo-
stasis, in agreement with our data showing an overall patho-
genic role for intestinal inflammation in DIO-related metabolic
disease. Thus, a combination of cues from both cells of theD 5-ASA WT mice from axillary lymph nodes, 2 weeks after immunization with
hallenged HFD WT and HFD 5-ASA WT mice 2 weeks after immunization with
esent mean ± SEM.
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intestinal immune system, as we have described, and innate
pathways within the intestinal epithelium collaborates to regulate
intestinal barrier function and downstream glucose homeostasis
during DIO.
We further show that inhibition of low-grade gut inflammation
with a gut-specific anti-inflammatory agent, 5-ASA, during HFD
feeding can alter systemic glucose metabolism. Treatment with
gut anti-inflammatory agents, including 5-ASA and Balsalazide,
has beneficial effects on the intactness of the gut epithelial
barrier in IBD models (Di Paolo et al., 1996; Liu et al., 2009).
We observed similar beneficial effects of 5-ASA on gut barrier
function during HFD feeding, which are linked to reduced
levels of inflammatory cytokines, such as TNF-a and IFNg, that
can directly worsen barrier leakage of gut bacteria (Barreau
et al., 2010; Beaurepaire et al., 2009). Accordingly, similar
alterations in intestinal IFNg-producing cells contribute to gut
barrier defects in the setting of DIO. In addition to its well-known
role as a COX-2 inhibitor, 5-ASA has PPARg agonistic effects,
which also contribute to our observed anti-inflammatory pheno-
type (Rousseaux et al., 2005). We noted increased PPARg
activity from bowel T cells of HFD 5-ASA-fed mice and that
PPARg contributes to 5-ASA inhibitory effects on IFNg produc-
tion by intestinal T cells in vitro. Interestingly, PPARg induction
in T cells can also bolster Treg function and numbers in
other tissues, including VAT (Cipolletta et al., 2012). However,
systemic effects of PPARg agonism in fat or liver are unlikely
in our study due to minimal metabolic effects seen in HFD
5-ASA-fed Rag1null mice and Beta7null mice, the lack of changes
in adipogenesis gene expression in VAT and SAT, and the lack
of detectable compound in VAT of HFD 5-ASA-fed mice. Thus,
intestinal immune cell PPARg may be another potential target
of action for immune modulatory drugs with PPARg agonistic
effects.
Consistent with other reports (Andrews et al., 2011), we noted
that 5-ASA could elicit changes in gut bacteria, including
increased bacterial diversity, and increased abundances
of Firmicutes, Clostridiales, and Ruminococcaceae. While these
changes could reflect primary effects of the drug, they could
also be secondary to reduced inflammation (Andrews et al.,
2011; Sartor, 2010). Reduced bacterial diversity and decreased
abundance of certain Clostridial groups and Ruminococcaceae
have been linked to increased inflammation in IBD (Sartor,
2010). Ruminococcaceae are prominent producers of short-
chain fatty acids, including butyrate, which have protective
activity in the intestine (Sartor, 2010). Thus, an interesting future
direction will be to tease out specific effects of 5-ASA-associ-
ated microbial influences on improving metabolic syndrome.
We were able to obtain beneficial effects on glucose
tolerance using a 5-ASA dose range of 150 mg/kg/day up to
1,500 mg/kg/day in mice, which using body surface area calcu-
lations (Reagan-Shaw et al., 2008) equates to approximate
equivalent doses of 730 mg/day up to 7 g/day in a 60 kg
human. Typical daily maintenance dosing of 5-ASA for mild
to moderate IBD varies but often ranges between 1.5 and
4.8 g/day (Burger and Travis, 2011). Thus, our work highlights
novel uses of such drugs in obesity-related IR, which may
require dosing not unlike existing protocols for IBD, though
controlled human clinical studies are needed to better validate
the effects and safety of different formulations of 5-ASA on IR.538 Cell Metabolism 21, 527–542, April 7, 2015 ª2015 Elsevier Inc.Improvements in systemic glucose tolerance with 5-ASA
treatment were found to be dependent on adaptive and gut
immune systems. The observed direct effect of 5-ASA in vitro
on purified intestinal dendritic cells modulating antigen-specific
T cell responses and IFNg production highlights potential
crosstalks between intestinal adaptive and innate immune
cells in mediating the effects of 5-ASA. The improvements in
intestinal and VAT inflammation in 5-ASA-treated or Beta7null
HFD-fed mice, with no effect on the inflammatory status of
systemic hematolymphoid organs such as the spleen, suggest
a possible linked circuit between adipose tissue and bowel
inflammation. Other studies have also suggested that bowel
inflammation may directly contribute to VAT inflammation
(Li et al., 2008; Teixeira et al., 2011). For instance, induction of
colitis during HFD leads to marked increases in VAT macro-
phages, lymphocytes, and neutrophils (Teixeira et al., 2011).
Such results raise the possibility of downstream trafficking be-
tween immune cells of the bowel and VAT or the possibility
that tolerance to leaked gut-soluble antigens in VAT is depen-
dent onmechanisms governed by the gut immune system. Addi-
tional studies are needed to determine whether bowel immune
cells routinely traffic to VAT and whether trafficking of gut-
derived anti-inflammatory immune cells (or reduced trafficking
of gut inflammatory cells) to VAT represents another mechanism
of action of 5-ASA.
Another contributing role of the gut immune system during
HFD may be in dictating downstream systemic inflammation to
soluble gut-derived antigens, including in metabolic tissues like
VAT, where inflammation directly impacts systemic disease.
Improved oral tolerance may also manifest as reduced inflam-
matory responses, including IgG against gut-derived endotoxin.
Oral tolerance to gut-derived antigens has been previously
linked to reduced inflammation in VAT and improvements in IR,
though the mechanisms were unknown (Wang et al., 2010). We
show that aberrant handling of gut antigen is likely due to the
gut inflammatory environment during HFD, which is reversible
with gut anti-inflammatory medication. HFD-induced low-grade
gut inflammation may be a key trigger for antigen-specific
T cell responses in VAT, linking the inflammatory phenotype
we describe in the bowel to downstream responses in VAT.
Overall, our work shows that low-grade inflammation in gut
immune cells is a functional alteration induced by HFD with im-
plications in IR (see Figure 7 for summary). Reducing low-grade
gut inflammation leads to reduced VAT inflammation and
improvements in metabolic homeostasis. These effects are
dependent on the adaptive immune system and gut immunity.
Thus, compounds that locally reduce gut inflammation may
represent a novel approach in the control of obesity-related IR.EXPERIMENTAL PROCEDURES
Mice
We purchased C57BL/6, Beta7null, Rag1null, and IFNgnull mice from Jackson
Laboratory. Lck-Cre+ PPARgfl/fl were generated in-house by breeding
Lck-Cre+ and PPARgfl/fl transgenic mice from Jackson Laboratory. Mice
were maintained in a pathogen-free, temperature-controlled environment on
a 12 hr light and dark cycle at the Toronto Medical Discovery Tower facility.
All mice used in comparative studies were male, age-matched, and littermates
where possible. Mice were fed either NCD (15 kcal% fat), HFD (Research
Diets, 60 kcal% fat, irradiated), or HFD 5-ASA starting at 6 weeks of age.
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Figure 7. Summary of Obese versus Lean Gut Milieu and the Impact of 5-ASA
In DIO, pro-inflammatory changes in immune cells contribute to increased gut permeability. These changes affect the gut locally but also have systemic
manifestations due to leaked bacterial and dietary components. The net result is systemic inflammation that fuels insulin resistance. 5-ASA, a gut-specific
anti-inflammatory drug, reverses this cascade of obesity-associated adverse events by restoring tolerance in the gut immune system, preserving gut barrier
function, and improving immune regulation.All studies were performed under the approval of Animal User Protocols by the
Animal Care Committee at the University Health Network. See Supplemental
Experimental Procedures.
Compounds and Treatment Diets
5-aminosalicylic acid powder (Sigma-Aldrich) was incorporated directly
into the HFD at two doses (150 mg/kg/day and 1,500 mg/kg/day) by
Research Diets Inc. 5-ASA was mixed into NCD at 1,500 mg/kg/day by Harlan
Laboratories.CMODE-K Cell Line
The murine intestinal epithelial cell line derived from C3H/He mice, MODE-K,
was a kind gift from Dr. K. Croitoru (University of Toronto). These cells
were propagated under standard protocol using DMEM (GIBCO) containing
10% FBS, 10 mMHEPES, 50 mM 2-mercaptoethanol, 50 mg/ml streptomycin,
and 50 U/ml penicillin. In MODE-K in vitro studies, we split cells at 70%–80%
confluency and seeded at a density of 3 3 105/well for treatment with
recombinant mouse IFNg (BioLegend) (5 or 10 ng/ml) for 24 hr. We mechani-
cally detached the cells for RNA isolation (QIAGEN).ell Metabolism 21, 527–542, April 7, 2015 ª2015 Elsevier Inc. 539
Metabolic Cage Studies
We placed mice in automated metabolic cages (Oxymax Systems, Columbus
Instruments) for 48 hr with airflow held constant at 0.5 l/min (Revelo et al.,
2015). See Supplemental Experimental Procedures.
Metabolic Studies
We measured body weights, GTTs, ITTs, serum insulin, and fat cell diameter
as previously described (Winer et al., 2009a). All GTTs were performed with
a 1.5 g/kg glucose i.p. injection unless indicated otherwise.
Histology
We fixed VAT, colons, and small bowel ileums from mice for 48 hr in 10%
buffered formalin before processing and H&E staining. We enumerated
crown-like structures (CLSs) in VAT by counting the number of adipocytes
completely surrounded by immune cells identified on H&E staining per 1003
low power field. Analysis of histochemical stains was performed in a blinded
fashion by two certified pathologists (S.W. and D.A.W.).
Isolation of VAT and Bowel-Associated Immune Cells
We isolated VAT-associated immune cells as previously described (Winer
et al., 2009a). For isolation of small intestine lamina propria immune cells,
we used the protocol previously described (Fritz et al., 2012) and processed
10 cm from the distal end of the small bowel (jejunum and ileum). For the
isolation of colonic lamina propria immune cells, we used the protocol previ-
ously described (Geddes et al., 2011). Following lamina propria isolations,
we passed immune cells through 70 mm strainers and used them for flow
cytometry.
Flow Cytometry
We stained single-cell suspensions for 30 min on ice with commercial anti-
bodies listed in Supplemental Experimental Procedures. We gated ILCs as
described (Kirchberger et al., 2013).
Human Bowel Samples and Immunohistochemistry
We obtained colon and small bowel samples from histologically normal
margins of surgical resection specimens for patients with sporadic colon
cancer at the Toronto General Hospital. All human specimens were obtained
with study approval by the Research Ethics Board for Human Subjects at
the University Health Network. See Supplemental Experimental Procedures
and Table S1.
Western Blotting
We injected mice i.p. with insulin (1.5 U/kg) or PBS and harvested and snap-
froze tissues after 10 min. To make tissue lysates, we mechanically homoge-
nized VAT, liver, and muscle tissues in ice-cold lysis buffer (Santa Cruz) and
centrifuged them at 14,000 g for 10 min at 4C. Supernatants were collected,
separated by SDS-PAGE, and probed for phospho-Akt (S473), total Akt, and
GAPDH (Cell Signaling Technology).
PPARg Activity Assay
We measured PPARg functional activity in T cell nuclear extracts using a
PPARg transcription factor binding assay following vendor’s instructions
(Thermo Scientific and Cayman Chemical Company). See Supplemental
Experimental Procedures.
In Vitro Co-Culture Studies
We purified bulk dendritic cells and T cells from murine small bowels and
spleens using a negative-selection DC or T cell isolation kit (StemCell
Technologies). We plated T cells at 5 3 105 cells/well with plate-bound
anti-CD3/CD28 (1 mg/ml, BioLegend). We dissolved 5-ASA in culturing media
(pH 7.3) and sterile-filtered the solution. Dissolved 5-ASA was added to
designated wells at concentrations of 0, 0.01, 0.1, and 1 mM. We collected
supernatants for cytokine measurements after 72 hr incubation. For DC-T
cell co-culture experiments, we pre-treated DCs with 0, 0.1, or 1.0 mM
5-ASA. After 24 hr, we washed the cells with PBS and co-cultured them
(1 3 104 cells/well) with OVA323-339 peptide and OT-II splenic or small bowel
T cells (5 3 104 cells/well) for 48 hr. Supernatants were collected at 48 hr for
cytokine measurement.540 Cell Metabolism 21, 527–542, April 7, 2015 ª2015 Elsevier Inc.Gut Permeability Assays
We performed FD4 permeability assays by orally gavaging overnight-fasted
mice with 0.4 mg/g body weight of FITC-conjugated dextran (Sigma) and col-
lecting plasma after 4 hr. We prepared standards and measured fluorescence
at 485/528 nm as previously described (Dong et al., 2014).
Endotoxin Measurements
We measured endotoxin levels in serum and adipose tissue using Pyrogene
Recombinant C endotoxin detection fluorescence kit (Lonza). We measured
mouse serum anti-LPS IgG antibody levels with a commercially available kit
(Chondrex).
Cytokine Measurements
Wemeasured serum cytokines by LuminexMultiplex cytokine assay (Millipore,
run by the UHN Microarray Center) and quantified IL-10 and IFNg in superna-
tants of anti-CD3/CD28-stimulated splenocytes or bowel immune cells
(Winer et al., 2009b) by ELISA (BioLegend).
qPCR
We extracted total RNA from isolated or cultured cells using a RNeasy Mini Kit
(QIAGEN), and for subcutaneous adipose tissue (SAT) and VAT we used
a RNeasy Lipid Extraction kit (QIAGEN). We reverse-transcribed the RNA
by random primers with M-MLV (Invitrogen). We performed qPCR with a
7900HT PCR system (Applied Biosystems) using SYBR Green Master Mix re-
agent (Applied Biosystems). Each sample was run in triplicate and normalized
to housekeeping genes, 18s or GAPDH. We calculated relative fold changes
in gene expression normalized to 18s or GAPDH by the DDCT method using
the equation 2DDCT. The results are shown as fold changes compared to
the control group. See Supplemental Experimental Procedures for primer
sequences.
Oral Tolerance Studies
We administered OVA in the form of drinking water (1 mg/ml) for 7 days
to NCD-, HFD-, or HFD 5-ASA-fed mice to induce oral tolerance. Average
consumption was similar across different groups, at 5 ml per day. Following
oral tolerance induction, we immunized animals with or without oral tolerance
induction subcutaneously with OVA/CFA (50 mg per side) on both sides of
the chest. Axillary draining lymph nodes and VAT were collected 7 days
following immunization and subjected to immunological analysis, including
OVA323-339/I-A
b tetramer staining and OVA-induced cytokine production
and proliferation in vitro. See Supplemental Experimental Procedures.
To measure OVA-specific Tregs, we stained VAT immune cells with a 1:200
dilution of PE-conjugated OVA323-339/I-A
b or control hCLIP/I-Ab tetramers
(NIH Tetramer Core Facility) in FBS-supplemented RPM-I for 4 hr at 37C,
followed by antibody staining for other surface antigens and Foxp3.
HPLC and Gut Microbiome Sequencing
See Supplemental Experimental Procedures.
Statistical Analyses
Statistical significance between two means was assessed with an unpaired,
two-sided t test. In figure legends, where specified, the number of biological
experiments is listed as the n value, followed by number of pooled mouse
samples. All data represent mean ± SEM. Statistical significance was set at
p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2015.03.001.
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